Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16385265 | 0.91 | ATM (0.39) | MAPTALDH1A1HTTBRD4PTGDR2 | |
| SCHEMBL17616633 | 0.91 | MRGPRX4 (0.37) | MAPTALDH1A1MRGPRX4RAB9ANPSR1 | |
| SCHEMBL16273764 | 0.91 | PTGDR2 (0.33) | BRD4PTGDR2PTGER1MRGPRX4FFAR4 | |
| SCHEMBL17616593 | 0.91 | FFAR1 (0.36) | MAPTALDH1A1HTTPTGDR2PTGER1 | |
| SCHEMBL17616570 | 0.90 | PTGER1 (0.37) | MAPTALDH1A1HTTPTGDR2PTGER1 | |
| SCHEMBL17616631 | 0.88 | L3MBTL1 (0.44) | MAPTALDH1A1HTTMRGPRX4RAB9A | |
| SCHEMBL8856034 | 0.88 | MAPT (0.45) | MAPTALDH1A1HTTPTGDR2RAB9A | |
| SCHEMBL15856695 | 0.87 | FFAR4 (0.37) | PTGER1MRGPRX4FFAR4FFAR1 | |
| SCHEMBL16920772 | 0.86 | MAPT (0.33) | MAPTALDH1A1HTTMRGPRX4RAB9A | |
| SCHEMBL17744718 | 0.86 | PTGER1 (0.41) | MAPTALDH1A1PTGER1FFAR4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675072-B2 | Tetrazolinone compound and application of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-13 | — | — | US | disclosed |
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | CYP2E1, MT-CO2, CASP3 | MAPT 3398/4885ALDH1A1 409/4885HTT 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.